IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3551
+0.0333 (+10.3480%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3218
Open0.3218
Bid0.3500 x 5000
Ask0.3990 x 5000
Day's Range0.3152 - 0.3700
52 Week Range0.2600 - 0.5600
Volume1,891,341
Avg. Volume681,013
Market Cap32.96M
Beta2.25
PE Ratio (TTM)-2.45
EPS (TTM)-0.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical

    LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for iBio, Inc. (NYSE: IBIO ), following which we have published a ...

  • PR Newswire4 days ago

    Aethlon Medical Announces Large-Scale Production Collaboration

    SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®.  iBio is a leading developer of plant-based biopharmaceuticals. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

  • GlobeNewswire4 days ago

    iBio Announces Manufacturing Collaboration with Aethlon Medical

    NEW YORK, Oct. 16, 2017-- iBio, Inc., a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the establishment of an agreement with Aethlon Medical, ...

  • Capital Cube7 days ago

    ETFs with exposure to iBio, Inc. : October 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What Are The Drivers Of iBio Inc’s (IBIO) Risks?
    Simply Wall St.15 days ago

    What Are The Drivers Of iBio Inc’s (IBIO) Risks?

    If you are a shareholder in iBio Inc’s (AMEX:IBIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017
    Capital Cube16 days ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 0.15 million, Net Earnings of USD -4.33 million. Change in operating cash flow of -33.42% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more (Read more...)

  • Capital Cube18 days ago

    ETFs with exposure to iBio, Inc. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire18 days ago

    iBio Appoints James Abbey, Ph.D. as Vice President of Strategic Business Development

    NEW YORK, Oct. 02, 2017-- iBio, Inc., a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today the appointment of James Abbey, Ph.D. as Vice ...

  • Capital Cubelast month

    ETFs with exposure to iBio, Inc. : September 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswirelast month

    iBio, Inc. Intellectual Property Update

    NEW YORK, Sept. 20, 2017-- iBio, Inc., a leading provider of plant-based biotechnology for developing and manufacturing biological products, provided an update on recent patents and inventions.. On September ...

  • GlobeNewswirelast month

    iBio Makes NYSE MKT Section 610(b) Public Announcement

    NEW YORK, Sept. 19, 2017-- iBio, Inc.– iBio, a leader in developing plant-based biopharmaceuticals, today announced that, as previously disclosed in its Annual Report on Form 10- K for the year ended June ...

  • iBio, Inc. :IBIO-US: Earnings Analysis: 2017 By the Numbers : September 19, 2017
    Capital Cubelast month

    iBio, Inc. :IBIO-US: Earnings Analysis: 2017 By the Numbers : September 19, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Aviragen Therapeutics Inc, Newlink Genetics Corporation, Altimmune, Inc., Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, AVIR-US, NLNK-US, ALT-US, NKTR-US, ... Read more (Read more...)

  • GlobeNewswirelast month

    iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products

    NEW YORK, Sept. 18, 2017-- iBio, Inc.– iBio, with its subsidiary, iBio CDMO LLC in Bryan/College Station, Texas, has partnered with TheoremDx, Inc., in Edina, Minnesota, to develop proteins for rapid diagnostic ...

  • PR Newswire3 months ago

    AzarGen Biotechnologies Granted European Patent for Plant-Made PRODUCTION OF RECOMBINANT HUMAN SURFACTANT PROTEIN-B

    STELLENBOSCH, South Africa , July 25, 2017 /PRNewswire/ -- AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa ), announced that it has received grant status for the patent application: PRODUCTION ...

  • GlobeNewswire3 months ago

    iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital

    NEW YORK, July 24, 2017-- iBio, Inc., a leader in developing plant-based biopharmaceuticals, announced today that it has entered into a $16 million common stock purchase agreement with Lincoln Park Capital ...

  • SmarterAnalyst3 months ago

    Wednesday’s Biotech Movers: Ibio Inc (IBIO) Rallies, Ocular Therapeutix Inc (OCUL) Tumbles, Alder Biopharmaceuticals Inc (ALDR) Dives

    Ibio Inc (NYSEMKT:IBIO) shares are rising fast in Wednesday’s trading session. "For this project, AzarGen's synthetic promoters are being tested with the objective of including the top performer in iBio's proprietary protein production vector," said Robert Erwin, ibio's President. Ibio develops drugs for a range of fibrotic diseases such as pulmonary fibrosis, while AzarGen is a biotechnology company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants.

  • PR Newswire3 months ago

    US Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology

    STELLENBOSCH, South Africa , July 12, 2017 /PRNewswire/ -- AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa ) announced that it has received grant status for the patent application: SYNTHETIC ...

  • Capital Cube3 months ago

    ETFs with exposure to iBio, Inc. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to iBio, Inc. : June 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
    Capital Cube5 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Johnson & Johnson, Aviragen Therapeutics Inc, Newlink Genetics Corporation, Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, JNJ-US, AVIR-US, NLNK-US, ... Read more (Read more...)

  • Marketwired6 months ago

    iBio, Inc. Provides Corporate Update at Annual Shareholders Meeting

    iBio, Inc. , a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Shareholders Meeting held in Bryan, TX.

  • Capital Cube6 months ago

    ETFs with exposure to iBio, Inc. : April 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to iBio, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017
    Capital Cube7 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis iBio, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Johnson & Johnson, Aviragen Therapeutics Inc, Newlink Genetics Corporation, PharmAthene, Inc., Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, JNJ-US, ... Read more (Read more...)